Video

Leiomyosarcoma Patient Discusses Treatment Roadmap, Challenges

Author(s):

Lauren Santye, Assistant Editor

Beth Wallace discusses various treatments for leiomyosarcoma, including doxorubicin (Adriamycin), nicknamed the red devil.

Beth Wallace discusses various treatments for leiomyosarcoma, including doxorubicin (Adriamycin), nicknamed the red devil.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
GLP-1, Diabetes, Type 2 Diabetes | Image Credit: © neirfy | stock.adobe.com
January 20th 2025

ASHP Midyear: Expert Discusses GLP-1 Medications and Incretin Mimetics for Diabetes Care

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
Woman holding pink breast cancer awareness ribbon -- Image credit: marina_li_1 | stock.adobe.com
January 20th 2025

From Abemaciclib to Trastuzumab Deruxtecan: Highlights From the 2024 San Antonio Breast Cancer Symposium

Douglas Braun, PharmD, RPh, CPH, CSP
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Red blood cells, hematology -- Image credit: Rasi | stock.adobe.com
January 19th 2025

From Blinatumomab to Venetoclax: Highlights From the 66th American Society of Hematology Annual Meeting and Exposition

Douglas Braun, PharmD, RPh, CPH, CSP
Microscopic view of metastatic breast cancer cells development and progression | Image Credit: © ratirath - stock.adobe.com
January 18th 2025

Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2– Metastatic Breast Cancer

Alexandra Gerlach, Associate Editor